Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inaticabtagene Autoleucel in Refractory SLE-related ITP
NCT06826430Phase 1Recruiting
- Sponsor
- Juventas Cell Therapy Ltd.
- Start
- Mar 2025
- Primary completion
- Mar 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of inaticabtagene autoleucel in immune thrombocytopenia (ITP) and systemic lupus erythematosus (SLE), sponsored by Juventas Cell Therapy Ltd. Primary endpoints: Incidence of Treatment-related Adverse Events at 28 days and Safe dosage for a single infusion at 28 days. Started Mar 2025; status: recruiting.
02
Drugs
inaticabtagene autoleucel
03
Conditions
immune thrombocytopenia (ITP)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06826430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06826430.